Table 5 Clinical characteristics and outcomes of AAV patients treated with avacopan in the literature
Author, Country, Year | Number of patients | Age | Organ involvement | Definition of remission | Outcomes |
|---|---|---|---|---|---|
Zonozi, USA, 2024 [20] | 92 | 59 ± 17 | • Renal: 71 (77%) • Pulmonary: 48 (52%) | No signs or symptoms of vasculitis activity and ≤5 mg prednisolone | • Remission at 26 w: 61 (90%) • Remission at 52 w: 32 (84%) • Relapse: 3 (3%) |
Draibe, Spain, 2024 [22] | 29 | 56 (IQR 46.5–67.5) | • Renal: 24 (79.3%) • Pulmonary: 9 (31.0%) | BVAS 0 | • Remission: 25 (86.2%) • Relapse: 4 (13.7%) |
Falde, Spain, 2024 [23] | 15 | 66 (IQR 52–72) | • Diffuse alveolar hemorrhage: 15 (100%) • Renal: 9 (60%) | BVAS 0 with complete discontinuation of prednisone | • Remission: 10 (66%) • Relapse: 0 (0%) |
Barr, Canada, 2024 [24] | 4 | 59–80 | • eGFR < 15 ml/min per 1.73 m2: 4 (100%) | No signs or symptoms of vasculitis activity | • Remission: 0 (0%) |
Chalkia, UK, 2024 [25] | 8 | 64 (17–80) | • Hypoxic pulmonary hemorrhage: 8 (100%) | Complete resolution of lung symptoms | • Complete resolution; 8 (100%) • Survival and sustained remission: 8 (100%) |
Zimmermann, Germany, 2024 [26] | 39 | 64 (IQR 51–72) | • Renal: 33 (85%) • Pulmonary: 20 (51%) | BVAS 0 and ≤7.5 mg prednisolone | • Remission at 6 months; 28 (87.5%) • Sustained remission at 12 months: 21 (91%) • Relapse: 4 (10%) |
The present study | 21 | 77 (IQR 66–81) | • Renal: 15 (71.4%) • Pulmonary: 11 (52.4%) | BVAS 0 and ≤7.5 mg prednisolone | • Remission at 6 months; 20 (95.2%) • Remission at 12 months: 19 (90.5%) • Relapse: 3 (14.3%) |